The meaning of low-grade inflammation in clinically quiescent inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 30, Issue 4, 2014, Pages 365-369

  Moss, Alan C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Colitis; Histology; Outcomes; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; INFLIXIMAB; MESALAZINE; MUCIN; STEROID;

CELL INFILTRATION; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; HISTOLOGY; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY CELL; LAMINA PROPRIA; LOW GRADE INFLAMMATION; MAGNIFYING ENDOSCOPY; NARROW BAND IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; RECTUM BIOPSY; REMISSION; REVIEW; ULCERATIVE COLITIS; COLONIC NEOPLASMS; GASTROINTESTINAL ENDOSCOPY; IMMUNOLOGY; METABOLISM; PATHOLOGY; RECURRENT DISEASE; RISK FACTOR;

C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INFLAMMATION; PROGNOSIS; RECURRENCE; RISK FACTORS;

EID: 84902255890     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000082     Document Type: Review

References (37)

1. Bouguen G, Levesque BG, Feagan BG, et al. Treat to target: A proposed new paradigm for the management of Crohn's disease. ClinGastroenterol Hepatol 2013. [Epub ahead of print]
2. Moss AC. Therapeutic drug monitoring, mucosal healing, deep remission: The path to nirvana in Crohn's disease? Clin Gastroenterol Hepatol 2014; 12:432-433.
3. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141:1194-1201.
4. Jenkins D, Balsitis M, Gallivan S, et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The BritishSociety of Gastroenterology Initiative. J Clin Pathol 1997; 50:93-105.
5. Rubio CA, Johansson C, Uribe A, Kock Y. A quantitative method of estimating inflammation in the rectal mucosa. IV. Ulcerative colitis in remission. Scand J Gastroenterol 1984; 19:525-530.
6. Jenkins D, Goodall A, Drew K, Scott BB. What is colitis? Statistical approach to distinguishing clinically important inflammatory change in rectal biopsy specimens. J Clin Pathol 1988; 41:72-79.
7. Geboes K, Riddell R,Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000; 47:404-409.
8. Geboes K, Dalle I. Influence of treatment on morphological features of mucosal inflammation. Gut 2002; 50 (Suppl 3):III37-III42.
9. Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. Br Med J 1956; 1:1315-1318.
10. Truelove SC, Hambling MH. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium: A report on a controlled therapeutic trial. Br Med J 1958; 2:1072-1077.
11. Odze R, Antonioli D, Peppercorn M, Goldman H. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol 1993; 17:869-875.
12. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50:667-671.
13. Rutgeerts P, Diamond RH,Bala M, et al.Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63:433-442.
14. Geboes K, Rutgeerts P, Olson A, Marano CW. Infliximab treatment results in the reduction of inflammation and inflammatory markers in the mucosa of patients with ulcerative colitis: The ACT 1 trial experience. Gut 2005; 54 (Suppl VII):A62.
15. Geboes K, Rutgeerts P, Opdenakker G, et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin 2005; 21:1741-1754.
16. Baars JE, Nuij VJ, Oldenburg B, et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 2012; 18:1634-1640.
17. Rosenberg L, LawlorG, Zenlea T, et al. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 2013; 19:779-784.
18. Rosenberg L, Nanda KS, Zenlea T, et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol 2013; 11:991-996.
19. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9:483-489.
20. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32:174-178.
21. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120:13-20.
22. Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on long-term outcomes in ulcerative colitis patients with mucosal healing. Gastroenterology 2012; 142 (S1):S653.
23. Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: A case-control study. Clin Gastroenterol Hepatol 2013; 11:1601-1608.
24. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: A cohort study. Gastroenterology 2007; 133:1099-1105.
25. Hefti MM, Chessin DB, Harpaz NH, et al. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum 2009; 52:193-197.
26. Burger D, Thomas S, Walsh A, et al. Depth of remission may not predict outcome of UC over 2 years. Gut 2011; 60 (S1):A133.
27. Froslie KF, Jahnsen J, Moum B A, Vatn M H. Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort. Gastroenterology 2007; 133:412-422.
28. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15:1295-1301.
29. Colombel JF, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014; 12:414.e5-422.e5.
30. Isomoto H, Uehara R, Hayashi T, et al. Magnifying endoscopic findings can predict clinical outcome during long-term follow-up of more than 12 months in patients with ulcerative colitis. Gastroenterol Res Pract 2013; 2013:671576.
31. Nishio Y, Ando T, Maeda O, et al. Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis. Gut 2006; 55:1768-1773.
32. Turcotte JF, Wong K, Mah SJ, et al. Increased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel disease. Clin Transl Gastroenterol 2012; 3:e19.
33. Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11:707-712.
34. Ordas I, Rimola J, Rodriguez S, et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. Gastroenterology 2014; 146:374-382.
35. Saboury B, Salavati A, Brothers A, et al. FDG PET/CT in Crohn's disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity. Eur J Nucl Med Mol Imaging 2014; 41:605-614.
36. Ananthakrishnan AN, Korzenik JR, Hur C. Can mucosal healing be a costeffective endpoint for biologic therapy in Crohn's disease? A decision analysis. Inflamm Bowel Dis 2013; 19:37-44.
37. Bouguen G, Levesque BG, Pola S, et al. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. Clin Gastroenterol Hepatol 2013. [Epub ahead of print]